29336 Federal Register / Vol. 66, No. 104 / Wednesday, May 30, 2001 / Notices

documents, business management

technical assistance may be obtained

from: Glynnis Taylor, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Program Announcement

01038.

Centers for Disease Control and

Prevention (CDC), 2920 Brandywine

Road, Room 3000, Atlanta, GA 30341–

4146, Telephone number: (770) 488–

2752, Email address: gld1@cdc.gov.

For program technical assistance,

contact: Amy DeGroff, Program Services

Branch, Division of Cancer Prevention

and Control, National Center for

Chronic Disease Prevention and Health

Promotion, Centers for Disease Control

and Prevention (CDC), 4770 Buford

Highway, NE., Mailstop K–57, Atlanta,

GA 30341–3724, Telephone number:

(770) 488–4248, Email address:

asd1@cdc.gov.

Dated: May 22, 2001.

Henry S. Cassell III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 01–13498 Filed 5–29–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Medical Devices Dispute Resolution

Panel of the Medical Devices Advisory

Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Medical Devices

Dispute Resolution Panel of the Medical

Devices Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

scientific disputes between the Center

for Devices and Radiological Health and

sponsors, applicants, and

manufacturers.

Date and Time: The meeting will be

held on June 4, 2001, 10:30 a.m. to 5

p.m.

Location: Corporate Bldg., conference

room 20B, 9200 Corporate Blvd.,

Rockville, MD.

Contact: Les Weinstein, Center for

Devices and Radiological Health (HFZ–

5), Food and Drug Administration, 9200

Corporate Blvd., Rockville, MD 20850,

301–443–6220, ext. 119, FAX 301–827–

2565, lsw@cdrh.fda.gov, or FDA

Advisory Committee Information Line,

1–800–741–8138 (301–443–0572) in the

Washington, DC area), code 10232.

Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will discuss,

make recommendations, and vote

regarding a scientific dispute between

the agency and Lifecore Biomedical,

Inc., related to the approvability of a

premarket approval application for

Intergel, an adhesion prevention

solution. Background information and

questions for the committee will be

available to the public on June 1, 2001,

on the Internet at http://www.fda.gov/

cdrh/panelmtg.html.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by May 31, 2001. Oral

presentations from the public will be

scheduled between approximately 10:30

a.m. to 11 a.m. Near the end of the

committee deliberations, a 30-minute

open public session will be conducted

for interested persons to address issues

specific to the dispute before the

committee. Time allotted for each

presentation may be limited. Those

desiring to make formal oral

presentations should notify the contact

person before May 31, 2001, and submit

a brief statement of the general nature of

the evidence or arguments they wish to

present, the names and addresses of

proposed participants, and an

indication of the approximate time

requested to make their presentation.

FDA regrets that it was unable to

publish this notice 15 days prior to the

June 4, 2001, Medical Devices Dispute

Resolution Panel of the Medical Devices

Advisory Committee meeting. Because

the agency believes there is some

urgency to bring this issue to public

discussion and qualified members of the

Medical Devices Dispute Resolution

Panel of the Medical Devices Advisory

committee were available at this time,

the Commissioner of Food and Drugs

concluded that it was in the public

interest to hold this meeting even if

there was not sufficient time for the

customary 15-day public notice.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: May 24, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01–13639 Filed 5–25–01; 3:08 pm]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment

Request; Leukemia and Other

Hematological Diseases Among

Cleanup Workers in Ukraine Following

the Chornobyl Accident

SUMMARY: In compliance with the

requirement of Section 3506(c)(2)(A) of

the Paperwork Reduction Act of 1995,

for opportunity for public comment on

proposed data collection projects, the

National Cancer Institute, the National

Institutes of Health (NIH) will publish

periodic summaries of proposed

projects to be submitted to the Office of

Management and Budget (OMB) for

review and approval.

Proposed Collection

Title: Leukemia and Other

Hematological Diseases Among Cleanup

Workers in Ukraine Following the

Chornobyl Accident. Type of

Information Collection Request: New.

Need and Use of Information Collection:

A case-control study will be conducted

to investigate the risk of radiationinduced leukemia and other

hematological diseases among

Chernobyl cleanup workers in Ukraine.

Cases and controls (or proxies) will be

interviewed to provide details of their

work during the Chornobyl clean-up

operation. The interview responses

combined with environmental

measurements will permit individual

bone marrow dose estimates to be

calculated for each case and control.

Dose estimates will be used to calculate

the risk of leukemia and other

hematological diseases associated with

low-dose and low dose-rate radiation

exposure. This information, which is

essential for radiation protection, is

currently not available and standards

presently are based on information

available only by extrapolation from

high-dose, high dose-rate data on Abomb survivors in Japan. Frequency of

Response: One time only. Affected

Public: Ukrainian Chornobyl clean-up

workers. Type of respondents: Cases,

controls, and proxies for deceased

subject. Estimated Number of

Respondents: 700. Estimated Number of

Responses per Respondent: Variable,

about 50. Average Burden Hours Per

Response: 0.75 hour. Estimated Total

Annual Burden Hours Requested: 400

hours (interviews to be conducted over

18-month period). There are no Capital

Costs, Operating Costs, and/or

Maintenance Costs to report.

Federal Register / Vol. 66, No. 104 / Wednesday, May 30, 2001 / Notices 29337

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Evaluate whether

the proposed collectionof information is

necessary for the proper performance of

the National Cancer Institute, including

whether the information will have

practical utility; (2) evaluate the

accuracy of the NCI’s estimate of the

burden of the proposed collection of

information, including the validity of

the methodology and assumptions used;

(3) enhance the enhance the quality

utility, and clarity of the information to

be collected; (4) minimize the burden of

the collection of information on those

who are to respond, including the use

of appropriate automated, electronic,

mechanical, or other technological

collection techniques or other forms of

information technology.

FOR FURTHER INFORMATION CONTACT: To

request more information on the

proposed project or to obtain a copy of

the data collection plans and

instruments, contact Dr. Terry L.

Thomas, National Cancer Institute, EPS

7100, 6120 Executive Boulevard,

Rockville, MD, 29892–7238, or call the

non-toll-free number (301) 496–6600.

Comments Due Date: Comments

regarding this information collection are

best assured of having their full effect if

received on or before July 30, 2001.

Dated: May 16, 2001.

Reesa Nichols,

NCI Project Clearance Liaison.

[FR Doc. 01–13484 Filed 5–29–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Improving

DNA, RNA and Protein availability in Fixed

Tissue.

Date: June 15, 2001.

Time: 8 a.m. to 2 p.m.

Agenda: To review and evaluate grant

applications.

Place: National Cancer Institute, 6130

Executive Boulevard, Conference Room F,

Rockville, MD 20852.

Contact Person: Gerald G. Lovinger,

Scientific Review Administrator, Grants

Review Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8101, Rockville, MD

20892–7405, 301/496–7987.

Any interested person may file written

comments with the committee by forwarding

the statement to the Contact Person listed on

this notice. The statement should include the

name, address, telephone number and when

applicable, the business or professional

affiliation of the interested person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: May 23, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–13539 Filed 5–29–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections 55b(c)(4)

and 552(b)(6), Title 5 U.S.C., as

amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel Research in

State and Community Tobacco Control.

Date: June 17–18, 2001.

Time: 6:30 PM to 5 PM.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn, 8120 Wisconsin

Avenue, Bethesda, MD 20814.

Contact Person: C.M. Kerwin, Scientific

Review Administrator, Special Review and

Resources Branch, Division of Extramural

Activities, National Cancer Institute, National

Institutes of Health, 6116 Executive

Boulevard, Room 8039, Rockville, MD

20892–7405, 301/496–7421.

Any interested person may file written

comments with the committee by forwarding

the statement to the Contact Person listed on

this notice. The statement should include the

name, address, telephone number and when

applicable, the business or professional

affiliation of the interested person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: May 23, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–13540 Filed 5–29–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Spores in

Skin Cancer.

Date: June 21–22, 2001.

Time: 8 a.m. to 6 p.m.